Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03532971 · ClinicalTrials.gov registry record
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 100
- Enrollment target
NCT03532971 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 100 participants.
The verdict
NCT03532971 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This research study is evaluating the reactivation of BK virus in patients who have undergone allogeneic hematopoietic-cell transplantation.
Interventions
- OTHER Symptom index questionnaire
- DIAGNOSTIC_TEST BK polyomavirus PCR
- OTHER quality of life questionnaires
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2020-09-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03532971
The ClinicalTrials.gov registry entry for NCT03532971 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Symptom index questionnaire is the first listed.
NCT03532971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03532971 about?
NCT03532971 is a clinical study titled "Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes". This research study is evaluating the reactivation of BK virus in patients who have undergone allogeneic hematopoietic-cell transplantation.
What is the current status of trial NCT03532971?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2018-07-30. Estimated completion is 2020-09-14.
What interventions are being tested in trial NCT03532971?
The interventions under investigation include: Symptom index questionnaire (OTHER), BK polyomavirus PCR (DIAGNOSTIC_TEST), quality of life questionnaires (OTHER).
Who is sponsoring clinical trial NCT03532971?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.